



an Open Access Journal by MDPI

Epigenetic Regulation of Solid Tumors

Guest Editors:

Dr. Donghong Zhang

Raybiotech, Atlanta, GA 30092,
USA

Dr. Yuning Hou

Cancer Animal Models Shared
Resource, Winship Cancer
Institute, Emory University,
Atlanta, GA 30322, USA

Dr. Xina Xie

The First Affiliated Hospital of
Shenzhen University, Shenzhen
518000, China

Deadline for manuscript
submissions:

closed (31 January 2024)

Message from the Guest Editors

Dear Colleagues,

Tumors are aggressive diseases with a high mortality rate and a costly treatment process. As the majority of cancer cases are firstly diagnosed at an advanced stage and with metastasis, the current management of cancer faces serious challenges, despite the development of advanced therapeutics. Therefore, employing cutting-edge bio-informatics, sequence technology and molecular biology to develop novel biomarkers for the accurate screening, detection, diagnosis, and prognosis prediction of cancer is essential in order to enhance patients' survival rate.

Increasing evidence indicates that epigenetic modifications, including DNA/RNA methylation, histone modifications, and non-coding RNAs (ncRNAs), have gained substantial attention in recent years, as it is now well established that these aberrations are significant biomarkers for tumor diagnosis, prognosis, and treatment response.

For this Special Issue, we invite basic and clinical oncologists to submit their contributions, including reviews, new methods, and original research, related to the role of epigenetics in tumor diagnosis and prognosis.



mdpi.com/si/182135

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)